Industry Briefs: November 5, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: November 5, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

Agere Pharmaceuticals has expanded its cGMP spray-dry capabilities. Read More

Charles River has agreed to acquire a majority ownership of Vital River. Read More

Cytovance Biologics has been awarded a biopharmaceutical development and manufacturing contract by Fountain BioPharma. Read More

Eli Lilly has announced a $140-million expansion to the company’s Indianapolis insulin manufacturing operations. Read More

Integrated Project Services has opened a new office São Paulo, Brazil. Read More

Pharmalink has entered into a contract with Patheon for the manufacturing of Nefecon, for treating the underlying pathology of progressive IgA nephropathy, the most common form of primary glomerulonephritis and a leading cause of end-stage renal disease.

Wacker Biotech and XL-protein have agreed to produce PASylated biopharmaceuticals. Read More

People News

Astellas has named Jeffrey Bloss vice-president of scientific and medical affairs. Read More

Cedarburg Hauser Pharmaceuticals has appointed John K. Lynch as chief scientific officer. Read More

Patheon has appointed Michael Lehmann as head of global pharmaceutical development services. Read More

Teva has announced several changes to its executive leadership team. Allan Oberman has been named president and CEO of Teva Americas Generics, and Jill DeSimone has been appointed as senior vice-president and general manager of Teva Global Women’s Health. William S. Marth will retire as president and CEO of Teva Americas. Read More

Following its acquisition of Actavis, Watson has announced a new global generics management team, including Siggi Olafsson, as president of the division, and several other appointments. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy

Click here